Physician profile
Nathan Klein
NPI 1457792350
$5,276.97
in general payments reported to CMS, 2019-2025
22 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $189 · 2021: $419 · 2022: $990 · 2023: $1,149 · 2024: $1,136 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.49 |
| Travel and Lodging | $246.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,025.84 | 2019-2025 | Eysuvis, Clareon, Tryptyr |
| Sun Pharmaceutical Industries INC. | $886.09 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $659.55 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $381.37 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $361.98 | 2021-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $285.17 | 2020-2022 | |
| Thea Pharma INC. | $253.89 | 2022-2025 | Iyuzeh |
| Intuitive Surgical, INC. | $246.97 | 2023 | Da Vinci Surgical System |
| Novartis Pharmaceuticals Corporation | $205.34 | 2020-2023 | |
| Dompe US, INC. | $146.86 | 2024-2025 | Oxervate |
| Abbvie INC. | $118.02 | 2022-2025 | |
| Glaukos Corporation | $115.39 | 2021-2025 | Idose, Idosetr, Istent Infinite |
| Aerie Pharmaceuticals, INC. | $104.83 | 2019-2021 | |
| Shire North American Group INC | $104.32 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $93.22 | 2023-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $83.17 | 2023-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Astellas Pharma US INC | $28.03 | 2024 | Izervay |
| Harrow Eye, LLC | $23.12 | 2024 | Vevye |
| Santen INC. | $21.60 | 2023 | Verkazia |
| Allergan, INC. | $21.60 | 2022 | |
| Sight Sciences, INC. | $17.25 | 2023 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.